1-2 of 2
Pamela Downs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Gertjan J.L. Kaspers, Noa E. Wijnen, Joost B. Koedijk, Sae Ishimaru, Renske Benedictus, Ellen C. Van Opstal, Harm Van Tinteren, C. Michel Zwaan, Noha Biserna, Pamela Downs, Yvonne Duong, Yasser Mostafa Kamel, Jonas Abrahamsson, Nira Arad-Cohen, Nicole Bodmer, Luis Castillo, Daniel Cheuk, Vitor Costa, Barbara De Moerloose, Jose Maria Fernandez Navarro, Linda Fogelstrand, Bianca F. Goemans, Henrik Hasle, Olafur G. Jonsson, Zhanna Kovalova, Monica C. Munthe-Kaas, Ulrika Norén-Nyström, Sauli Palmu, Ramune Pasauliene, Kadri Saks, Anne Maria Tierens, Dominik Turkiewicz, Cornelis Jan Pronk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1532.
https://doi.org/10.1182/blood-2023-181792
Published: 2023
Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 3937.
https://doi.org/10.1182/blood-2019-121736
Published: 2019